Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MULGONET: An interpretable neural network framework to integrate multi-omics data for cancer recurrence prediction and biomarker discovery.

Fundamental research·2026
Same author

Establishing the Asia & Pacific Bioinformatics Joint Congress: a historic milestone in regional bioinformatics collaboration.

Briefings in bioinformatics·2025
Same author

P4ward: An Automated Modeling Platform for Protac Ternary Complexes.

Journal of chemical information and modeling·2025
Same author

Angiostatin-a novel SARS-CoV-2 inhibitor and biomarker underlying COVID-19 pathophysiology.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Investigation of the HLA locus in autopsy-confirmed progressive supranuclear palsy.

Immunobiology·2025
Same author

Utilizing Neurons to Interrogate Cancer: Integrative Analysis of Cancer Omics Data with Deep Learning Models.

IEEE reviews in biomedical engineering·2025
Same journal

IdopNetworks: How to infer the individualized genetic architecture of genomics for precision medicine.

Drug discovery today·2026
Same journal

Organoid-AI platforms need integrated governance in drug discovery.

Drug discovery today·2026
Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026
Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
Same journal

Targeting the GLP-1 receptor pathways for dual management of obesity and depression.

Drug discovery today·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Structure-based drug design to augment hit discovery.

Subha Kalyaanamoorthy1, Yi-Ping Phoebe Chen

  • 1Faculty of Science, Technology and Engineering, La Trobe University, Australia.

Drug Discovery Today
|August 4, 2011
PubMed
Summary
This summary is machine-generated.

This review explores in silico strategies for hit identification in drug discovery. It discusses challenges and solutions to improve the hit-to-lead phase for structure-based drug design (SBDD).

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Related Experiment Videos

Last Updated: May 30, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Area of Science:

  • Computational chemistry and cheminformatics
  • Drug discovery and development
  • Medicinal chemistry

Background:

  • Drug discovery involves hit identification and lead optimization.
  • Structure-based drug design (SBDD) relies on 3D target structures.
  • Technological advancements have increased available computational tools.

Purpose of the Study:

  • To review in silico strategies for hit identification.
  • To discuss challenges in the hit-to-lead phase.
  • To enhance the success rate of SBDD.

Main Methods:

  • Literature review of in silico tools and strategies.
  • Analysis of computational approaches for hit identification.
  • Examination of challenges and solutions in hit-to-lead progression.

Main Results:

  • A significant increase in computational software and tools over the past decade.
  • Identification of key in silico strategies applicable to hit identification.
  • Discussion of challenges impacting the hit-to-lead transition.

Conclusions:

  • In silico methods are crucial for modern drug discovery.
  • Addressing hit-to-lead challenges can accelerate SBDD.
  • Continued development of computational tools will advance drug design.